Clinical Trial Update: Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating panitumumab given with CAPOX and subsequently with capecitabine and pelvic radiation for rectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Panitumumab (panitumumab)

Snippet

Sponsor: NSABP Foundation Inc | Conditions: Rectal Cancer, Neoplasm Metastasis | Phase 2 | Status: WITHDRAWN